抑郁症的药物治疗进展及艾氯胺酮的应用前景

被引：24

作者：

林芳波 ^{[1
]}

侯德仁 ^{[1
]}

唐秋萍 ^{[2
]}

机构：

[1] 中南大学湘雅三医院神经内科

[2] 中南大学湘雅三医院临床心理科

来源：

南方医科大学学报 | 2017年 / 37卷 / 04期

关键词：

抑郁症; 发病机制; 药物治疗; 艾氯胺酮;

D O I：

暂无

中图分类号：

R749.4 [情感性精神病];

学科分类号：

100205 ;

摘要：

抑郁症是一种病因和发病机制不明的精神障碍。抑郁症的发生可能与神经递质分泌减少、神经细胞的凋亡、炎症反应、肠道菌群失调等多种因素有关。目前临床常用的抗抑郁药SSRIs、SNRIs、Na SSA、SARIs类药物虽有一定的效果,但难以缓解抑郁患者所有的症状。近年来研究发现艾氯胺酮主要通过N-甲基-D天冬氨酸受体发挥强大而持久的抗抑郁作用。本文就抑郁症的发病机制、药物治疗研究进展和艾氯胺酮治疗抑郁症的机制、疗效及其应用前景进行综述。目前艾氯胺酮抗抑郁的作用机制未明确,临床尚未普遍应用,但其能迅速缓解抑郁症的症状等优点一定会有广泛的应用前景。

引用

页码：567 / 569

页数：3

共 17 条

[1] Rapid antidepressant effect of ketamine correlates with astroglial plasticity in the hippocampus [J].

Ardalan, Maryam ;

Rafati, Ali H. ;

Nyengaard, Jens R. ;

Wegener, Gregers .

BRITISH JOURNAL OF PHARMACOLOGY, 2017, 174 (06) :483-492

[2]

Transferring the blues: Depression-associated gut microbiota induces neurobehavioural changes in the rat[J] . John R. Kelly,Yuliya Borre,Ciaran O’ Brien,Elaine Patterson,Sahar El Aidy,Jennifer Deane,Paul J. Kennedy,Sasja Beers,Karen Scott,Gerard Moloney,Alan E. Hoban,Lucinda Scott,Patrick Fitzgerald,Paul Ross,Catherine Stanton,Gerard Clarke,John F. Cryan,Timothy G. Dinan.Journal of Psychiatric Research . 2016

[3]

Serotonin levels in the dorsal raphe nuclei of both chipmunks and mice are enhanced by long photoperiod, but brain dopamine level response to photoperiod is species-specific[J] . Ryosei Goda,Tsuyoshi Otsuka,Ayaka Iwamoto,Misato Kawai,Satomi Shibata,Mitsuhiro Furuse,Shinobu Yasuo.Neuroscience Letters . 2015

[4]

Altered serotonin and dopamine transporter availabilities in brain of depressed patients upon treatment with escitalopram: A[123 I]β-CIT SPECT study[J] . A. Rominger,P. Cumming,M. Brendel,G. Xiong,C. Zach,S. Karch,K. Tatsch,P. Bartenstein,C. la Fougère,W. Koch,O. Pogarell.European Neuropsychopharmacology . 2015 (6)

[5] Augmentation Therapy With Serial Intravenous Ketamine Over 18 Months in a Patient With Treatment Resistant Depression [J].

Hassamal, Sameer ;

Spivey, Margaret ;

Pandurangi, Ananda K. .

CLINICAL NEUROPHARMACOLOGY, 2015, 38 (05) :212-216

[6] Correlation between the human fecal microbiota and depression [J].

Naseribafrouei, A. ;

Hestad, K. ;

Avershina, E. ;

Sekelja, M. ;

Linlokken, A. ;

Wilson, R. ;

Rudi, K. .

NEUROGASTROENTEROLOGY AND MOTILITY, 2014, 26 (08) :1155-1162

[7]

A review of ketamine in affective disorders: Current evidence of clinical efficacy, limitations of use and pre-clinical evidence on proposed mechanisms of action[J] . Marie Naughton,Gerard Clarke,Olivia O′Leary,John F. Cryan,Timothy G. Dinan.Journal of Affective Disorders . 2013

[8]

Monoamine neurocircuitry in depression and strategies for new treatments[J] . Michel Hamon,Pierre Blier.Progress in Neuropsychopharmacology ＆ Biological Psychiatry . 2013

[9]

Gut–brain axis: how the microbiome influences anxiety and depression[J] . Jane A. Foster,Karen-Anne McVey Neufeld.Trends in Neurosciences . 2013 (5)

[10] Increased Expression of the Anti-Apoptotic Protein Bcl-xL in the Brain is Associated with Resilience to Stress-Induced Depression-Like Behavior [J].

Dygalo, Nikolay N. ;

Kalinina, Tatyana S. ;

Bulygina, Veta V. ;

Shishkina, Galina T. .

CELLULAR AND MOLECULAR NEUROBIOLOGY, 2012, 32 (05) :767-776

← 1 2 →